Literature DB >> 31577095

Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.

Arrigo F G Cicero1, Olta Allkanjari, Gian Maria Busetto, Tommaso Cai, Gaetano Larganà, Vittorio Magri, Gianpaolo Perletti, Francesco Saverio Robustelli Della Cuna, Giorgio Ivan Russo, Kostantinos Stamatiou, Alberto Trinchieri, Annabella Vitalone.   

Abstract

During the last years, pharmaceutical innovations in primary care are dramatically less frequent and will be even more rare in the next future. In this context, preclinical and clinical research oriented their interest toward natural compounds efficacy and safety, supporting the development of a new "nutraceutical" science. Medicinal plants, in the form of plant parts or extracts of them, are commonly used for the treatment of prostate diseases such as benign hypertrophy, prostatitis and chronic pelvic pain syndrome. The pharmacological properties searched for the treatment of prostatic diseases are anti-androgenic, anti-estrogenic, antiproliferative, antioxidant and anti-inflammatory. The most studied and used medicinal plants are Serenoa repens, Pygeum africanum and Urtica dioica. Other promising plants are Cucurbita pepo, Epilobium spp, Lycopersum esculentum, Secale cereale, Roystonea regia, Vaccinium macrocarpon. In parallel, epidemiological studies demonstrated that diet may play an important role on incidence and development of prostatic diseases. The Mediterranean diet is rich of elements with anti-oxidant properties that act as a protective factor for prostatic cancer. Similarly, low intake of animal protein, high intake of fruits and vegetable, lycopene and zinc are a protective factor for benign prostatic hyperplasia (BPH). Serenoa repens in the treatment of symptoms of BPH has been tested either alone or, more frequently, in combination with other medicinal plants, alpha-blockers and inhibitors of 5- alpha reductase (5-ARI). Recent meta-analyses found the effectiveness of Serenoa repens similar or inferior of that of finasteride and tamsulosin but clearly higher than that of placebo in the treatment of mild and moderate low urinary tract symptoms (LUTS), nocturia and discomfort. Clinical trials showed potential synergistic effect of Serenoa repens with other medicinal plants and drugs. In addition to Serenoa repens, there are many other medicinal plants for which clinical evidence is still controversial. Urtica dioica, Pygeum africanum and Curcubita pepo can be considered as an adjunct to the common therapies and their use is supported by studies showing improvement of symptoms and flowmetric indices. Lycopene and selenium are natural products with antioxidant and anti-inflammatory action. The combination of lycopene and selenium with Serenoa repens was able to reduce inflammation in histological prostate sections and to further improve symptom scores and urinary flow in patients with BPH on tamsulosin treatment. Similar effects could be obtained with the use of other carotenoids, such as astaxanthin, and/or zinc. Efficacy on symptoms of patients with BPH of some polyphenols such as quercitin, equol and curcumin have been demonstrated by clinical studies. Pollen extract is a mixture of natural components able to inhibit several cytokines and prostaglandin and leukotriene synthesis resulting in a potent anti-inflammatory effect. Pollen extracts significantly improve symptoms, pain, and quality of life in patients affected by chronic pelvic pain syndrome and chronic prostatitis. Beta-sitosterol is a sterol able to improve urinary symptoms and flow measures, but not to reduce the size of the prostate gland. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide-signaling molecule with anti-inflammatory and neuroprotective effects that can have an interesting role in the management of chronic pelvic pain syndrome and chronic urological pain. Finally, several plant-based products have been subjected to preclinical, in vitro and in vivo, investigations for their potential pharmacological activity against prostate cancer. Some epidemiological studies or clinical trials evaluated the effects of beverages, extracts or food preparations on the risk of prostate cancer. Some plant species deserved more intense investigation, such as Camelia sinensis (green or black tea), Solanum lycopersicum (common tomato), Punica granatum (pomegranate), Glycine max (common soy) and Linum usitatissimum (linen).

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31577095     DOI: 10.4081/aiua.2019.3.139

Source DB:  PubMed          Journal:  Arch Ital Urol Androl        ISSN: 1124-3562


  16 in total

1.  Prostate Cancer Risk Connection to Immunity, Hormones, and the Microbiome.

Authors:  Jeffrey S Bland
Journal:  Integr Med (Encinitas)       Date:  2021-12

Review 2.  Molecular Mechanism of β-Sitosterol and its Derivatives in Tumor Progression.

Authors:  Xingxun Bao; Yanan Zhang; Hairong Zhang; Lei Xia
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 3.  Herbal nutraceutical treatment of chronic prostatitis-chronic pelvic pain syndrome: a literature review.

Authors:  Ochbayasakh Dashdondov; Junaid Wazir; Ganbolor Sukhbaatar; Reyaj Mikrani; Buyankhishig Dorjsuren; Nasrin Aktar; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2021-04-27       Impact factor: 2.370

4.  A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency.

Authors:  H V Sudeep; Jestin V Thomas; K Shyamprasad
Journal:  BMC Urol       Date:  2020-07-03       Impact factor: 2.264

Review 5.  Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia.

Authors:  Kensuke Mitsunari; Yasuyoshi Miyata; Tomohiro Matsuo; Yuta Mukae; Asato Otsubo; Junki Harada; Tsubasa Kondo; Tsuyoshi Matsuda; Kojiro Ohba; Hideki Sakai
Journal:  Molecules       Date:  2021-01-16       Impact factor: 4.411

Review 6.  Dietary Factors and Supplements Influencing Prostate Specific-Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials.

Authors:  Maria G Grammatikopoulou; Konstantinos Gkiouras; Stefanos Τ Papageorgiou; Ioannis Myrogiannis; Ioannis Mykoniatis; Theodora Papamitsou; Dimitrios P Bogdanos; Dimitrios G Goulis
Journal:  Nutrients       Date:  2020-09-29       Impact factor: 5.717

7.  Astaxantin and Isoflavones Inhibit Benign Prostatic Hyperplasia in Rats by Reducing Oxidative Stress and Normalizing Ca/Mg Balance.

Authors:  Alexander L Semenov; Ekaterina A Gubareva; Elena D Ermakova; Anastasia A Dorofeeva; Irina A Tumanyan; Ekaterina A Radetskaya; Maria N Yurova; Saied A Aboushanab; Osman N Kanwugu; Elena I Fedoros; Andrey V Panchenko
Journal:  Plants (Basel)       Date:  2021-12-12

Review 8.  Treatment of Benign Prostatic Hyperplasia by Natural Drugs.

Authors:  Eszter Csikós; Adrienn Horváth; Kamilla Ács; Nóra Papp; Viktória Lilla Balázs; Marija Sollner Dolenc; Maša Kenda; Nina Kočevar Glavač; Milan Nagy; Michele Protti; Laura Mercolini; Györgyi Horváth; Ágnes Farkas
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

Review 9.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11

Review 10.  Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: Emerging Insights.

Authors:  Giuseppe Giannaccare; Marco Pellegrini; Carlotta Senni; Federico Bernabei; Vincenzo Scorcia; Arrigo Francesco Giuseppe Cicero
Journal:  Mar Drugs       Date:  2020-05-01       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.